4Grieco A, forgione A, Giorgi A. Propafenone- related cholestatic hepatitis in an elderly patient. Ital Heart J, 2002,3:431 -434.
5Sharma SK, Balamurugan A, Saha PK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med,2002,166:916 - 919.
6Sherlock S, Dooley J. Disease of the lliver and biliary system.9thed [M]. Oxford: Blaekwell Scientific Pubilieations, 1993.322.
7Jimmerman HJ, Ishak KG. General aspects of drugsinducd liver disease[J]. Gastroenterol Clin North Am , 1995,24: 739.
8Zimmerman HJ, Ishak KG. General aspects of drugs-induced liver disease [ J ]. Gastroenterol Clin North Am, 1995,24 (4) :739.
9Speeg KV, Bay MK. Prevention and treatment of drug - induced liver disease[ J ]. Gastroenterol Clin Nprth Am, 1995,24(4 ) : 1027.
10Vasco A,Maria J,Rui MM. Development and validation of a clinical scale for the diagnosis of a drug-induced hepatitis [ J ]. Hepatology,1997,26 (3) :664-669.
2Benichou C.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11:272-276.
3Czaja AJ,Freese DK.Diagnosis and treatment of autoimmune hepatitis[J].Hepatology,2002,36:479-497.
4Ryan M,Desmond P.Liver toxicity.Could this be a drug reaction?[J].Aust Fam Physician,2001,30:427-431.
5Yuen MF,Tam S,Fung J,et al.Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection:a l-year prospective study[J].Aliment Pharmacol Ther,2006,24:1179-1186.
